



(86) Date de dépôt PCT/PCT Filing Date: 1998/07/14
(87) Date publication PCT/PCT Publication Date: 1999/01/28
(45) Date de délivrance/Issue Date: 2010/10/19
(85) Entrée phase nationale/National Entry: 2000/01/11
(86) N° demande PCT/PCT Application No.: US 1998/014520
(87) N° publication PCT/PCT Publication No.: 1999/003973
(30) Priorité/Priority: 1997/07/14 (US60/052,910)

(51) Cl.Int./Int.Cl. *C12N 5/00* (2006.01),
A61K 48/00 (2006.01), *C12N 15/86* (2006.01),
C12N 5/10 (2006.01), *A61K 35/12* (2006.01)

(72) Inventeurs/Inventors:
PITTENGER, MARK F., US;
GORDON, STEPHEN L., US;
MACKAY, ALASTAIR MORGAN, US

(73) Propriétaire/Owner:
OSIRIS THERAPEUTICS, INC., US

(74) Agent: SMART & BIGGAR

(54) Titre : REGENERATION DU MUSCLE CARDIAQUE A L'AIDE DE CELLULES SOUCHE MESENCHYMATEUSES
(54) Title: CARDIAC MUSCLE REGENERATION USING MESENCHYMAL STEM CELLS

(57) **Abrégé/Abstract:**

Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.



**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 5/00, 5/08, 5/10, 15/86, A61K 48/00	A1	(11) International Publication Number: WO 99/03973 (43) International Publication Date: 28 January 1999 (28.01.99)
(21) International Application Number: PCT/US98/14520 (22) International Filing Date: 14 July 1998 (14.07.98) (30) Priority Data: 60/052,910 14 July 1997 (14.07.97) US (71) Applicant (for all designated States except US): OSIRIS THERAPEUTICS, INC. [US/US]; 2001 Aliceanna Street, Baltimore, MD 21231-2001 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): PITTENGER, Mark, F. [US/US]; 108 Southway, Severna Park, MD 21146 (US). GORDON, Stephen, L. [US/US]; 6361 Gray Sea Way, Columbia, MD 21045 (US). MACKAY, Alastair, Morgan [US/US]; 4 Buttrick Court, No. 204, Timonium, MD 21093 (US). (74) Agents: SEMIONOW, Raina et al.; Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein, 6 Becker Farm Road, Roseland, NJ 07068 (US).		(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: CARDIAC MUSCLE REGENERATION USING MESENCHYMAL STEM CELLS (57) Abstract <p>Disclosed is a method for producing cardiomyocytes <i>in vivo</i> by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells <i>ex vivo</i> in a heart valve for implantation.</p>		

68975-237

5

10

15

CARDIAC MUSCLE REGENERATION USING MESENCHYMAL STEM CELLS

Background of the Invention

20 This invention relates to the replacement and regeneration of cardiac tissue and muscle.

This year over 300,000 Americans will die from congestive heart failure. The ability to augment weakened cardiac muscle would be a major advance in the treatment of cardiomyopathy and heart failure. Despite advances in the medical
25 therapy of heart failure, the mortality due to this disorder remains high, where most patients die within one to five years after diagnosis.

A common heart ailment in the aging population is improper heart valve function, particularly the aortic valve. Mechanical replacement valves are widely
30 used but require the patient to continually take blood thinners. Valves obtained from cadavers and xenographs (porcine) are also frequently used to replace a patient's own tissue. Valves are freeze-dried or chemically cross-linked using e.g., glutaraldehyde to stabilize the collagen fibrils and decrease antigenicity and

68975-237

proteolytic degradation. However, these valves remain acellular and often fail after several years due to mechanical strain or calcification. A replacement valve derived from biocompatible material that would allow ingrowth of the appropriate host cells and renewal of tissue over time would be preferred.

5

Mesenchymal stem cells (MSCs) are cells which are capable of differentiating into more than one type of mesenchymal cell lineage. Mesenchymal stem cells (MSCs) have been identified and cultured from avian and mammalian species including mouse, rat, rabbit, dog and human (See Caplan *et al.* 1991. J. of Ortho. Res. 9(5):641-650, and U.S. Patent Nos. 5,226,914 and 5,486,359). Isolation, purification and culture expansion of hMSCs is described in detail therein.

Summary of the Invention

In accordance with the present invention mesenchymal stem cells (MSCs) are used to regenerate or repair striated cardiac muscle that has been damaged through disease or degeneration. The MSCs differentiate into cardiac muscle cells and integrate with the healthy tissue of the recipient to replace the function of the dead or damaged cells, thereby regenerating the cardiac muscle as a whole. Cardiac muscle does not normally have reparative potential. The MSCs are used, for example, in cardiac muscle regeneration for a number of principal indications: (i) ischemic heart implantations, (ii) therapy for congestive heart failure patients, (iii) prevention of further disease for patients undergoing coronary artery bypass graft, (iv) conductive tissue regeneration, (v) vessel smooth muscle regeneration and (vi) valve regeneration. Thus the MSCs are also used to integrate with tissue of a replacement heart valve to be placed into a recipient. The MSCs, preferably autologous, repopulate the valve tissue, enabling proper valve function.

MSC cardiac muscle therapy is based, for example, on the following sequence: harvest of MSC-containing tissue, isolation/expansion of MSCs, implantation into the damaged heart (with or without a stabilizing matrix and biochemical manipulation), and *in situ* formation of myocardium. This approach is different from traditional tissue engineering, in which the tissues are grown *ex vivo* and implanted in their final differentiated form. Biological, bioelectrical and/or

biomechanical triggers from the host environment may be sufficient, or under certain circumstances, may be augmented as part of the therapeutic regimen to establish a fully integrated and functional tissue.

5 Accordingly, one aspect of the present invention provides a method for producing cardiomyocytes in an individual in need thereof which comprises administering to said individual a myocardium-producing amount of mesenchymal stem cells. The mesenchymal stem cells that are employed may be a homogeneous composition or may be a mixed cell population enriched in MSCs. Homogeneous
10 human mesenchymal stem cell compositions are obtained by culturing adherent marrow or periosteal cells; the mesenchymal stem cells may be identified by specific cell surface markers which are identified with unique monoclonal antibodies. A method for obtaining a cell population enriched in mesenchymal stem cells is described, for example, in U.S. Patent No. 5,486,359.

15

The administration of the cells can be directed to the heart, by a variety of procedures. Localized administration is preferred. The mesenchymal stem cells can be from a spectrum of sources including, in order of preference: autologous, allogeneic or xenogeneic. There are several embodiments to this aspect, including
20 the following.

In one embodiment of this aspect, the MSCs are administered as a cell suspension in a pharmaceutically acceptable liquid medium for injection. Injection, in this embodiment, can be local, *i.e.* directly into the damaged portion of the
25 myocardium, or systemic. Here, again, localized administration is preferred.

In another embodiment of this aspect, the MSCs are administered in a biocompatible medium which is, or becomes *in situ* at the site of myocardial damage, a semi-solid or solid matrix. For example, the matrix may be (i) an
30 injectible liquid which "sets up" (or polymerizes) to a semi-solid gel at the site of the damaged myocardium, such as collagen and its derivatives, polylactic acid or polyglycolic acid, or (ii) one or more layers of a flexible, solid matrix that is implanted in its final form, such as impregnated fibrous matrices. The matrix can

68975-237

be, for example, Gelfoam* (Upjohn, Kalamazoo, MI). The matrix holds the MSCs in place at the site of injury, *i.e.* serves the function of "scaffolding". This, in turn, enhances the opportunity for the administered MSCs to proliferate, differentiate and eventually become fully developed cardiomyocytes. As a result of
5 their localization in the myocardial environment they then integrate with the recipient's surrounding myocardium. These events likewise occur in the above liquid injectible embodiment, but this embodiment may be preferred where more rigorous therapy is indicated.

10 In another embodiment of this aspect, the MSCs are genetically modified or engineered to contain genes which express proteins of importance for the differentiation and/or maintenance of striated muscle cells. Examples include growth factors (TGF- β , IGF-1, FGF), myogenic factors (myoD, myogenin, Myf5, MRF), transcription factors (GATA-4), cytokines (cardiotrophin-1), members of
15 the neuregulin family (neuregulin 1, 2 and 3) and homeobox genes (Csx, tinman, NKx family). Also contemplated are genes that code for factors that stimulate angiogenesis and revascularization (*e.g.* vascular endothelial growth factor (VEGF)). Any of the known methods for introducing DNA are suitable, however electroporation, retroviral vectors and adeno-associated virus (AAV) vectors are
20 currently preferred.

Thus, in association with the embodiment of the above aspect using genetically engineered MSCs, this invention also provides novel genetically engineered mesenchymal stem cells and tissue compositions to treat the above
25 indications. The compositions can include genetically modified MSCs and unmodified MSCs in various proportions to regulate the amount of expressed exogenous material in relationship to the total number of MSCs to be affected.

The invention also relates to the potential of MSCs to partially differentiate
30 to the cardiomyocyte phenotype using *in vitro* methods. This technique can under certain circumstances optimize conversion of MSCs to the cardiac lineage by predisposing them thereto. This also has the potential to shorten the time required for complete differentiation once the cells have been administered.

73164-142

One aspect of the invention relates to use of mesenchymal stem cells for engraftment in a heart.

Another aspect of the invention relates to use of mesenchymal stem cells for engraftment in infarcted heart
5 tissue.

Another aspect of the invention relates to use of mesenchymal stem cells for engraftment in at least one damaged portion of heart tissue.

Another aspect of the invention relates to use of
10 human mesenchymal stem cells along with a diluent or carrier, for the preparation of a composition for engraftment in heart tissue of an individual.

Another aspect of the invention relates to a method for repopulating cells in a heart valve to be
15 implanted into a recipient heart, comprising contacting the heart valve with mesenchymal stem cells *ex vivo* wherein the mesenchymal stem cells infiltrate and repopulate the valve.

Another aspect of the invention relates to use of allogeneic human bone marrow-derived, culture-expanded
20 mesenchymal stem cells and a pharmaceutically acceptable isotonic liquid, in the preparation of a cell suspension for intravenous delivery, for engraftment in heart tissue of an individual.

Brief Description of the Drawings

Figures 1A - 1C show cardiac muscle injected, using a fine needle, with *in vitro* dye-labeled MSCs. The lipophilic dyes PKH26 (Sigma Chemical) or CM-Di
5 I (Molecular Probes) were utilized to label MSCs prior to being introduced into animals. These dyes remain visible when the tissue site is harvested 1-2 months later. We have also shown that such dyes do not interfere with the differentiation of MSCs in *in vitro* assays. Figure 1A shows the low magnification image of a rat heart which has been injected with dye labeled cells and later, a T-incision has been
10 made at the site. Figures 1A and 1B reveal the labeled MSCs in the ventricle wall viewed from the outer surface. Figure 1C shows a cross-section of the ventricle wall and that the cells are present in the outer 1-2 mm of the 3mm thick cardiac muscle.

Detailed Description of Preferred Embodiments

The proper environmental stimuli convert MSCs into cardiac myocytes. Differentiation of mesenchymal stem cells to the cardiac lineage is controlled by factors present in the cardiac environment. Exposure of MSCs to a simulated cardiac environment directs these cells to cardiac differentiation as detected by
20 expression of specific cardiac muscle lineage markers. Local chemical, electrical and mechanical environmental influences alter pluripotent MSCs and convert the cells grafted into the heart into the cardiac lineage.

Early in embryonic development following the epithelia-mesenchyme
25 transition, the presumptive heart mesenchyme from the left and right sides of the body migrate to the ventral midline. Here, interaction with other cell types induces continued cardiogenesis. *In vitro* conversion of MSCs to cardiomyocytes is tested by co-culture or fusion with murine embryonic stem cells or cardiomyocytes, treatment of MSCs with cardiac cell lysates, incubation with specific soluble
30 growth factors, or exposure of MSCs to mechanical stimuli and electrical stimulation.

A series of specific treatments applicable to MSCs to induce expression of

cardiac specific genes are disclosed herein. The conditions are effective on rat, canine and human MSCs. Treatments of MSCs include (1) co-culturing MSCs with fetal, neonatal and adult rat cardiac cells, (2) use of chemical fusogens (*e.g.*, polyethylene glycol or sendai virus) to create heterokaryons of MSCs with fetal,
5 neonatal and adult cardiomyocytes, (3) incubating MSCs with extracts of mammalian hearts, including the extracellular matrix and related molecules found in heart tissue, (4) treatment of MSCs with growth factors and differentiating agents, (5) mechanical and/or electrical stimulation of MSCs, and (6) mechanically and/or electrically coupling MSCs with cardiomyocytes. MSCs that progress
10 towards cardiomyocytes first express proteins found in fetal cardiac tissue and then proceed to adult forms. Detection of expression of cardiomyocyte specific proteins is achieved using antibodies to, for example, myosin heavy chain monoclonal antibody MF 20 (MF20), sarcoplasmic reticulum calcium ATPase (SERCA1) (mAb 10D1) or gap junctions using antibodies to connexin 43.

15

Cardiac injury promotes tissue responses which enhance myogenesis using implanted MSCs. Thus, MSCs are introduced to the infarct zone to reduce the degree of scar formation and to augment ventricular function. New muscle is thereby created within an infarcted myocardial segment. MSCs are directly
20 infiltrated into the zone of infarcted tissue. The integration and subsequent differentiation of these cells is characterized, as described above. Timing of intervention is designed to mimic the clinical setting where patients with acute myocardial infarction would first come to medical attention, receive first-line therapy, followed by stabilization, and then intervention with myocardial
25 replacement therapy if necessary.

Of the four chambers of the heart, the left ventricle is primarily responsible for pumping blood under pressure through the body's circulatory system. It has the thickest myocardial walls and is the most frequent site of myocardial injury
30 resulting from congestive heart failure. The degree of advance or severity of the congestive heart failure ranges from those cases where heart transplantation is indicated as soon as a suitable donor organ becomes available to those where little or no permanent injury is observed and treatment is primarily prophylactic.

The severity of resulting myocardial infarction, *i.e.* the percentage of muscle mass of the left ventricle that is involved can range from about 5 to about 40 percent. This represents affected tissue areas, whether as one contiguous ischemia or the sum of smaller ischemic lesions, having horizontal affected areas from about 2 cm² to about 6 cm² and a thickness of from 1-2 mm to 1-1.5 cm. The severity of the infarction is significantly affected by which vessel(s) is involved and how much time has passed before treatment intervention is begun.

10 The mesenchymal stem cells used in accordance with the invention are, in order of preference, autologous, allogeneic or xenogeneic, and the choice can largely depend on the urgency of the need for treatment. A patient presenting an imminently life threatening condition may be maintained on a heart/lung machine while sufficient numbers of autologous MSCs are cultured or initial treatment can
15 be provided using other than autologous MSCs.

The MSC therapy of the invention can be provided by several routes of administration, including the following. First, intracardiac muscle injection, which avoids the need for an open surgical procedure, can be used where the MSCs are in an injectible liquid suspension preparation or where they are in a biocompatible medium which is injectible in liquid form and becomes semi-solid at the site of damaged myocardium. A conventional intracardiac syringe or a controllable arthroscopic delivery device can be used so long as the needle lumen or bore is of sufficient diameter (*e.g.* 30 gauge or larger) that shear forces will not damage the
20 MSCs. The injectible liquid suspension MSC preparations can also be administered intravenously, either by continuous drip or as a bolus. During open surgical procedures, involving direct physical access to the heart, all of the described forms of MSC delivery preparations are available options.

30 As a representative example of a dose range is a volume of about 20 to about 50 μ l of injectible suspension containing 10-40 x 10⁶ MSCs/ml. The concentration of cells per unit volume, whether the carrier medium is liquid or solid remains within substantially the same range. The amount of MSCs delivered

will usually be greater when a solid, "patch" type application is made during an open procedure, but follow-up therapy by injection will be as described above. The frequency and duration of therapy will, however, vary depending on the degree (percentage) of tissue involvement, as already described (*e.g.* 5-40% left
5 ventricular mass).

In cases having in the 5-10% range of tissue involvement, it is possible to treat with as little as a single administration of one million MSCs in 20-50 μ l of injection preparation. The injection medium can be any pharmaceutically
10 acceptable isotonic liquid. Examples include phosphate buffered saline (PBS), culture media such as DMEM (preferably serum-free), physiological saline or 5% dextrose in water (D5W).

In cases having more in a range around the 20% tissue involvement severity
15 level, multiple injections of 20-50 μ l ($10-40 \times 10^6$ MSCs/ml) are envisioned. Follow-up therapy may involve additional dosings.

In very severe cases, *e.g.* in a range around the 40% tissue involvement severity level, multiple equivalent doses for a more extended duration with long
20 term (up to several months) maintenance dose aftercare may well be indicated.

The present invention is further illustrated, but not limited, by the following example.

25

Example 1

Implantation of MSCs in normal cardiac muscle

In using MSCs, it is desirable to maintain cell-cell contact *in vivo* for the conversion of MSCs to the muscle lineage. Environmental signals identified above act in concert with mechanical and electrical signaling *in vivo* to lead to cardiac
30 differentiation.

Primary human MSCs (hMSCs) are introduced into athymic rat myocardial tissue by direct injection. The integration of implanted cells, their subsequent

differentiation, formation of junctions with cardiac cells, and their long-term survival are characterized with light microscopy, histology, confocal immunofluorescence microscopy, electron microscopy and *in situ* hybridization.

5 Whether human MSCs are appropriately grafted into cardiac muscle of athymic rats (strain HSD:RH-RNU/RNU), which lack the immune responses necessary to destroy many foreign cells, is also examined.

10 Rat MSCs are grafted into the heart muscles of rats. To analyze the injected cells over several weeks and to minimize the possibility of immune system rejection, MSCs are harvested from Fisher 344 rats, the same inbred strain (identical genotype) as the intended MSC recipients.

15 The MSCs can be marked in a variety of ways prior to their introduction into the recipient. This makes it possible to trace the fate of the MSCs as they proliferate and differentiate in the weeks following the MSC implant. Several methods are utilized to positively identify the injected cells: membrane lipid dyes PKH26 or CM-DI I and genetic marking with adeno-associated virus (AAV) or retroviruses, such as Maloney murine leukemia virus expressing green fluorescent
20 protein (GFP) or galactosidase. PCR is also used to detect the Y chromosome marker of male cells implanted into female animals. The dye-labeled cells are readily detected and offer the simplest method to directly follow the injected cells. This method is reliable for times out to at least 4 weeks. On the day of introduction to recipient animals, MSCs are trypsinized and labeled with CM-DI I
25 according to the recommendations of the manufacturer (Molecular Probes). Subconfluent monolayer cultures of MSCs are incubated with 5mM CM-DI I in serum-free medium for 20 minutes, trypsinized, washed twice in excess dye-free medium, and utilized for injection.

30 Alternatively, MSCs are genetically marked prior to injections, such as by using AAV-GFP vector. This vector lacks a selectable marker but mediates high-level expression of the transduced genes in a variety of post-mitotic and stem cell types. Recombinant AAV-GFP is added to low density monolayers of MSCs

in low serum. Following a four hour incubation at 37°C, the supernatant is removed and replaced with fresh media. At 96 hours after transduction, cells are assayed for green fluorescent protein (GFP) activity. Typically 50% of the cells express the transduced gene. Unselected MSCs on a clonal line, isolated by
5 limiting dilution, are utilized for injection. Cells are collected following trypsin treatment, washed and used at high concentrations for injection (10 to 100 million cells per ml).

To test whether the hMSCs became cardiomyocytes in the heart
10 environment, the hearts of ten week old athymic rats were injected with dye labeled or GFP-labeled human MSCs. All procedures were performed under strict sterile conditions. The animals were placed in a glass jar containing a methoxyflurane anesthesia soaked sponge. Under sterile conditions, a 20 mm anterior thoracotomy was performed, and following visualization of the left ventricle, 10 µl of the cell
15 suspension, containing 10,000 to 100,000 MSCs in serum-free medium were injected into the left ventricular apex using a 30 gauge needle. The procedure was performed rapidly with endotracheal intubation and mechanical ventilation assist. The incision was closed with sutures. Ventilation assist was normally unnecessary after a short period following chest closure. Figure 1A shows the low
20 magnification image of a rat heart which was injected with dye labeled cells and later, a T-incision had been made at the site to reveal the injected cells in the ventricular wall. Figure 1A is a gross photo of the incised heart. Figures 1B and 1C reveal the labeled MSCs in the ventricle wall. Figure 1C shows that the cells were present in the outer 1-2 mm of the 3 mm thick rat cardiac muscle.

25

When sacrificed, the heart is removed, examined by light microscopy for the presence of vascular thrombi or emboli, paraffin-embedded, and sectioned. The histology of serial sections is examined to determine the fate of dye-stained cells. Sections are then tested for immunohistochemical markers of cardiac muscle
30 in the areas of the introduced MSCs to ascertain whether donor MSCs have differentiated into cardiomyocytes *in vivo*. Implantation surgeries are carried out on animals to be sacrificed at 1, 2, 4, and 6 weeks (4 animals at each time point) and the hearts which received implants are analyzed histologically and

68975-237

immunologically.

For phenotypic characterization, the hearts are removed and processed for histology by immunofluorescence microscopy. Differentiation of MSCs is
5 determined by the immunofluorescence localization of sarcomeric myosin heavy chain, SERCA1 and phospholamban. The sequence-specific antibody to gap junction protein connexin 43, which is commercially available (Zymed) and detects gap junctions in cardiac tissue is used.

10 MSCs are also implanted in biomatrix materials to determine if enhanced grafting would be observed, such as type I collagen. The MSCs are rapidly mixed with the matrix in a small volume and injected into the ventricle wall. The biomatrices are used at concentrations of 0.1 mg/ml or greater. For example, the biomatrices may be used at concentrations of 1 to 3 mg/ml containing 10 to 100
15 million cells/ml. The tissue is analyzed at times of 1, 2, 4, and 6 weeks as described above.

Example 2

Regeneration of heart valves using MSCs

20 Xenograft or homograft valves are made acellular by freeze-drying, which leads to cellular death, or by enzymatic treatment followed by detergent extraction of cells and cell debris. This latter approach was taken by Vesely and coworkers with porcine valves to be repopulated with dermal or aortic fibroblasts. Curttil et al. 1997. J. Heart Valve Dis. May; 6(3):296-306 used a freeze-dried porcine valve and
25 attempted repopulation of the valve with human fibroblasts and endothelial cells. These studies were preliminary and limited to short term studies in vitro.

The acellular valve to be populated by autologous hMSCs is incubated with culture expanded hMSCs in a tumbling vessel to ensure loading of cells to all valve
30 surfaces. The valve is then cultured with the hMSCs for 1-2 weeks to allow the hMSCs to infiltrate and repopulate the valve. Within the culture vessel, the valve is then attached to a pump to allow the actuation of the valve leaflets and simulate the pumping motion present in the body. The valve is maintained in the pumping

WO 99/03973

PCT/US98/14520

mode for 1-2 weeks to allow cellular remodeling associated with the stresses of the pumping action. Once sufficient cellular remodeling has occurred, the valve is implanted into the body of the patient.

- 5 Another embodiment of this aspect of the invention is to first repopulate the valve with hMSCs and to later incubate the valve tissue during the pumping stage with autologous smooth muscle cells isolated from a vascular graft which will line the lumen of the valve.

73164-142

CLAIMS:

1. Use of mesenchymal stem cells for engraftment in a heart.
2. Use of mesenchymal stem cells for engraftment in
5 infarcted heart tissue.
3. Use of mesenchymal stem cells for engraftment in at least one damaged portion of heart tissue.
4. The use of any one of claims 1 to 3 wherein the mesenchymal stem cells are for use by injection.
- 10 5. The use of any one of claims 1 to 4 wherein the mesenchymal stem cells are for use systemically.
6. The use of any one of claims 1 to 5 wherein the mesenchymal stem cells are for use in an open surgical procedure.
- 15 7. The use of any one of claims 1 to 5 wherein the mesenchymal stem cells are in a pharmaceutically acceptable liquid injectable carrier.
8. The use of any one of claims 1 to 6 wherein the mesenchymal stem cells are in a biocompatible medium which
20 is injectable in liquid form and becomes semi-solid at the damaged portion of the heart tissue.
9. The use of claim 8 wherein the medium is selected from the group consisting of collagen and its derivatives, polylactic acid, polyglycolic acid and extracellular matrix.
- 25 10. The use of claim 3 or 6 wherein the mesenchymal stem cells are in a biocompatible medium which is a solid, flexible matrix.

73164-142

11. The use of claim 10 wherein the solid, flexible matrix comprises one or more fibrous layers impregnated with a semi-solid biocompatible medium.

12. The use of any one of claims 1 to 11 wherein the
5 mesenchymal stem cells are human.

13. The use of any one of claims 1 to 12 wherein the mesenchymal stem cells are autologous.

14. The use of any one of claims 1 to 12 wherein the mesenchymal stem cells are allogeneic.

10 15. The use of any one of claims 1 to 14 wherein at least a portion of the mesenchymal stem cells have been modified to contain exogenous genetic material.

16. The use of claim 15 wherein the exogenous genetic material codes for an expression product selected from the
15 group consisting of growth factors, myogenic factors, transcription factors, cytokines, homeobox genes, angiogenesis stimulating factors and revascularization enhancing factors.

17. Use of human mesenchymal stem cells along with a
20 diluent or carrier, for the preparation of a composition for engraftment in heart tissue of an individual.

18. A method for repopulating cells in a heart valve to be implanted into a recipient heart, comprising contacting the heart valve with mesenchymal stem cells
25 *ex vivo* wherein the mesenchymal stem cells infiltrate and repopulate the valve.

19. The method of claim 18 wherein the mesenchymal stem cells contact at least one damaged portion of the heart valve.

73164-142

20. The method of claim 18 or 19 wherein the mesenchymal stem cells are injected into the heart valve.

21. The method of any one of claims 18 to 20 wherein the mesenchymal stem cells are in a biocompatible medium
5 which is injectable in liquid form and becomes semi-solid at the damaged portion of the heart tissue.

22. The method of claim 21 wherein the medium is selected from the group consisting of collagen and its derivatives, polylactic acid, polyglycolic acid and
10 extracellular matrix.

23. The method of any one of claims 18 to 20 wherein the mesenchymal stem cells in a biocompatible medium which is a solid, flexible matrix.

24. The method of claim 23 wherein the solid, flexible
15 matrix comprises one or more fibrous layers impregnated with a semi-solid biocompatible medium.

25. The method of any one of claims 18 to 24 wherein the mesenchymal stem cells are human.

26. The method of any one of claims 18 to 25 wherein
20 the mesenchymal stem cells are autologous.

27. The method of any one of claims 18 to 25 wherein the mesenchymal stem cells are allogeneic.

28. The method of any one of claims 18 to 27 wherein at least a portion of the mesenchymal stem cells have been
25 modified to contain exogenous genetic material.

29. The method of claim 28 wherein the exogenous genetic material codes for an expression product selected from the group consisting of growth factors, myogenic

73164-142

factors, transcription factors, cytokines, homeobox genes, angiogenesis stimulating factors and revascularization enhancing factors.

30. The use of claim 1 wherein the heart is of a
5 patient suffering from congestive heart failure.

31. The use of claim 1 wherein the heart is of a patient suffering from myocardial infarction.

32. The use of claim 30 or 31, wherein the mesenchymal stem cells are in a matrix.

10 33. The use of claim 30 or 31, wherein the mesenchymal stem cells are for direct administration to the heart.

34. The use of claim 30 or 31, wherein the mesenchymal stem cells are in a pharmaceutically acceptable liquid carrier.

15 35. The use of claim 30 or 31, wherein the mesenchymal stem cells are for intravenous administration.

36. The use of claim 30 or 31, wherein the mesenchymal stem cells are autologous to the patient.

37. The use of claim 30 or 31, wherein the mesenchymal
20 stem cells are allogeneic to the patient.

38. The use of claim 30 or 31, wherein the mesenchymal stem cells are for administration via a catheter.

39. The use of claim 7, 19 or 36 wherein the mesenchymal stem cells are allogeneic human bone marrow-
25 derived, culture-expanded cells.

40. The use of any one of claims 1 to 3 wherein the mesenchymal stem cells are allogeneic human bone marrow-

73164-142

derived, culture-expanded cells suspended in a pharmaceutically acceptable isotonic liquid for intravenous delivery.

41. Use of allogeneic human bone marrow-derived,
5 culture-expanded mesenchymal stem cells and a pharmaceutically acceptable isotonic liquid, in the preparation of a cell suspension for intravenous delivery, for engraftment in heart tissue of an individual.
42. The use of claim 1 wherein the mesenchymal stem
10 cells are allogeneic human bone marrow-derived, culture-expanded mesenchymal stem cells suspended in a pharmaceutically acceptable isotonic liquid, for intravenous delivery in the heart of a patient suffering from congestive heart failure.
- 15 43. The use of claim 1 wherein the mesenchymal stem cells are allogeneic human bone marrow-derived, culture-expanded mesenchymal stem cells suspended in a pharmaceutically acceptable isotonic liquid, for intravenous delivery in the heart of a patient suffering from myocardial
20 infarction.

SMART & BIGGAR

OTTAWA, CANADA

PATENT AGENTS

1/2

FIG. 1A



FIG. 1B



WO 99/03973

PCT/US98/14520

2/2

FIG. 1C



SUBSTITUTE SHEET (RULE 26)